S
SOLENO THERAPEUTICS INC
NASDAQ: SLNO (Soleno Therapeutics, Inc.)
Last update: 2 hours ago67.51
3.33 (5.19%)
| Previous Close | 64.18 |
| Open | 65.46 |
| Volume | 1,606,570 |
| Avg. Volume (3M) | 1,798,060 |
| Market Cap | 3,587,819,520 |
| Price / Earnings (Forward) | 24.15 |
| Price / Sales | 81.03 |
| Price / Book | 12.83 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Diluted EPS (TTM) | -4.74 |
| Total Debt/Equity (MRQ) | 22.73% |
| Current Ratio (MRQ) | 19.64 |
| Operating Cash Flow (TTM) | -89.32 M |
| Levered Free Cash Flow (TTM) | -33.98 M |
| Return on Assets (TTM) | -52.40% |
| Return on Equity (TTM) | -105.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Soleno Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
2.1
| Analyst Consensus | 5.0 |
| Insider Activity | 1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 2.10 |
|
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.83% |
| % Held by Institutions | 109.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Carlyle Group Inc. | 30 Jun 2025 | 860,980 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 123.00 (Wells Fargo, 82.20%) | Buy |
| Median | 110.00 (62.94%) | |
| Low | 106.00 (Guggenheim, 57.01%) | Buy |
| Average | 112.25 (66.27%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 70.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 27 Aug 2025 | 106.00 (57.01%) | Buy | 67.68 |
| 07 Aug 2025 | 106.00 (57.01%) | Buy | 78.71 | |
| Wells Fargo | 20 Aug 2025 | 123.00 (82.20%) | Buy | 68.94 |
| HC Wainwright & Co. | 18 Aug 2025 | 110.00 (62.94%) | Buy | 68.09 |
| Oppenheimer | 07 Aug 2025 | 110.00 (62.94%) | Buy | 78.71 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HAHN MARK W | 64.27 | - | 10,046 | 645,656 |
| Aggregate Net Quantity | 10,046 | |||
| Aggregate Net Value ($) | 645,656 | |||
| Aggregate Avg. Buy ($) | 64.27 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HAHN MARK W | Director | 13 Oct 2025 | Acquired (+) | 10,046 | 64.27 | 645,656 |
| Date | Type | Details |
|---|---|---|
| 21 Oct 2025 | Announcement | Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET |
| 13 Oct 2025 | Announcement | Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors |
| 27 Aug 2025 | Announcement | Soleno Therapeutics to Participate in Upcoming September Conferences |
| 06 Aug 2025 | Announcement | Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results |
| 28 Jul 2025 | Announcement | Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |